Neutrophil extracellular traps and metabolic reprogramming in renal cell carcinoma: implications for tumor progression and immune-based therapeutics.

IF 8.4 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Cancer Biology & Medicine Pub Date : 2025-09-12 DOI:10.20892/j.issn.2095-3941.2025.0219

Asif Shahzad, Yueli Ni, Zhuoran Teng, Wenjing Liu, Honggang Bai, Yijian Sun, Kun Cui, Qiuxin Duan, Xiangjie Liu, Zhe Xu, Jinshan Zhang, Jiaojiao Xia, Rong Che, Ting Guo, Zhe Yang, Qiao Zhang

{"title":"Neutrophil extracellular traps and metabolic reprogramming in renal cell carcinoma: implications for tumor progression and immune-based therapeutics.","authors":"Asif Shahzad, Yueli Ni, Zhuoran Teng, Wenjing Liu, Honggang Bai, Yijian Sun, Kun Cui, Qiuxin Duan, Xiangjie Liu, Zhe Xu, Jinshan Zhang, Jiaojiao Xia, Rong Che, Ting Guo, Zhe Yang, Qiao Zhang","doi":"10.20892/j.issn.2095-3941.2025.0219","DOIUrl":null,"url":null,"abstract":"<p><p>Neutrophil extracellular traps (NETs) are web-like structures of DNA and proteins that are released by activated neutrophils. While originally identified as antimicrobial defense mechanisms, NETs are now recognized as key modulators of tumor progression. NETs interact with the tumor microenvironment and metabolic pathways in renal cell carcinoma (RCC), which promotes immune evasion and metastasis. This review explores the interplay between NET formation and metabolic reprogramming in RCC, highlighting the implications for immunotherapy resistance and therapeutic targeting. NET-associated signaling, immunometabolism disruption, and current strategies to inhibit NETs in preclinical and clinical settings are discussed. Targeting NETs may represent a promising adjunct in RCC therapy, particularly when integrated with immune checkpoint blockade.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20892/j.issn.2095-3941.2025.0219","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Neutrophil extracellular traps (NETs) are web-like structures of DNA and proteins that are released by activated neutrophils. While originally identified as antimicrobial defense mechanisms, NETs are now recognized as key modulators of tumor progression. NETs interact with the tumor microenvironment and metabolic pathways in renal cell carcinoma (RCC), which promotes immune evasion and metastasis. This review explores the interplay between NET formation and metabolic reprogramming in RCC, highlighting the implications for immunotherapy resistance and therapeutic targeting. NET-associated signaling, immunometabolism disruption, and current strategies to inhibit NETs in preclinical and clinical settings are discussed. Targeting NETs may represent a promising adjunct in RCC therapy, particularly when integrated with immune checkpoint blockade.

查看原文本刊更多论文

肾细胞癌中中性粒细胞胞外陷阱和代谢重编程：对肿瘤进展和免疫治疗的影响。

中性粒细胞胞外陷阱（NETs）是由活化的中性粒细胞释放的DNA和蛋白质的网状结构。虽然最初被确定为抗菌防御机制，但NETs现在被认为是肿瘤进展的关键调节剂。在肾细胞癌（RCC）中，NETs与肿瘤微环境和代谢途径相互作用，促进免疫逃避和转移。这篇综述探讨了RCC中NET形成和代谢重编程之间的相互作用，强调了免疫治疗抵抗和治疗靶向的意义。本文讨论了net相关信号、免疫代谢紊乱以及临床前和临床环境中抑制net的当前策略。靶向NETs可能是一种很有希望的RCC治疗辅助手段，特别是与免疫检查点阻断联合使用时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biology & Medicine Medicine-Oncology

CiteScore

9.80

自引率

3.60%

发文量

1143

审稿时长

12 weeks

期刊介绍： Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.